Amy W. ChungMusie GhebremichaelHannah RobinsonEric BrownIckwon ChoiSophie LaneAnne Sophie DugastMatthew K. SchoenMorgane RollandTodd J. SuscovichAlison E. MahanLarry LiaoHendrik StreeckCharla AndrewsSupachai Rerks-NgarmSorachai NitayaphanMark S. De SouzaJaranit KaewkungwalPunnee PitisuttithumDonald FrancisNelson L. MichaelJerome H. KimChris Bailey-KelloggMargaret E. AckermanGalit AlterMassachusetts Institute of TechnologyThayer School of Engineering at DartmouthDartmouth CollegeWalter Reed Army Institute of ResearchDuke UniversityThailand Ministry of Public HealthArmed Forces Research Institute of Medical Sciences, ThailandMahidol UniversityGlobal Solutions for Infectious Diseases2018-11-092018-11-092014-03-19Science Translational Medicine. Vol.6, No.228 (2014)19466242194662342-s2.0-84899105650https://repository.li.mahidol.ac.th/handle/123456789/34264The human phase 2B RV144 ALVAC-HIV vCP1521/AIDSVAX B/E vaccine trial, held in Thailand, resulted in an estimated 31.2% efficacy against HIV infection. By contrast, vaccination with VAX003 (consisting of only AIDSVAX B/E) was not protective. Because protection within RV144 was observed in the absence of neutralizing antibody activity or cytotoxic T cell responses, we speculated that the specificity or qualitative differences in Fc-effector profiles of nonneutralizing antibodies may have accounted for the efficacy differences observed between the two trials. We show that the RV144 regimen elicited nonneutralizing antibodies with highly coordinated Fc-mediated effector responses through the selective induction of highly functional immunoglobulin G3 (IgG3). By contrast, VAX003 elicited monofunctional antibody responses influenced by IgG4 selection, which was promoted by repeated AIDSVAX B/E protein boosts. Moreover, only RV144 induced IgG1 and IgG3 antibodies targeting the crown of the HIV envelope V2 loop, albeit with limited coverage of breakthrough viral sequences. These data suggest that subclass selection differences associated with coordinated humoral functional responses targeting strain-specific protective V2 loop epitopes may underlie differences in vaccine efficacy observed between these two vaccine trials.Mahidol UniversityMedicineArticleSCOPUS10.1126/scitranslmed.3007736